Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8075289 | 0.79 | — | — | |
| SCHEMBL8075293 | 0.79 | — | — | |
| SCHEMBL13810444 | 0.78 | ALDH1A1 (0.39) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL2236322 | 0.77 | HSD17B10 (0.43) | ALDH1A1CYP2C9HPGDALOX15CYP2C19 | |
| SCHEMBL2235856 | 0.77 | EPHX1 (0.38) | ALDH1A1CYP2C9HPGDALOX15CYP2C19 | |
| SCHEMBL9664023 | 0.76 | MEN1 (0.34) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL7450284 | 0.76 | ALDH1A1 (0.38) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL9256818 | 0.74 | LMNA (0.44) | ALDH1A1LMNASMN1; SMN2HPGDMEN1 | |
| SCHEMBL2234578 | 0.74 | ALDH1A1 (0.31) | ALDH1A1CYP2C9HPGDALOX15CYP2C19 | |
| SCHEMBL24393425 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307239-A4 | RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX | NIHON MEDIPHYSICS CO LTD (JP) | 2005-01-26 | — | — | EP | claimed |
| US-20040018147-A1 | Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2004-01-29 | — | — | US | claimed |
| EP-1307239-A1 | RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX | Nihon Medi-Physics Co., Ltd. (JP) | 2003-05-07 | — | — | EP | claimed |
| WO-2002009771-A1 | RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2002-02-07 | — | — | WO | claimed |
| US-8182789-B2 | Intermediate compound of technetium nitride complex for radiodiagnostic imaging | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2012-05-22 | — | — | US | disclosed |
| EP-1973923-B1 | INTERMEDIATE COMPOUND OF TECHNETIUM NITRIDE COMPLEX FOR RADIODIAGNOSTIC IMAGING | NIHON MEDIPHYSICS CO LTD (JP) | 2011-08-17 | — | — | EP | disclosed |
| US-20100160615-A1 | INTERMEDIATE COMPOUND OF TECHNETIUM NITRIDE COMPLEX FOR RADIODIAGNOSTIC IMAGING | NIHON MED-PHYSICS CO., LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
| US-7445765-B2 | Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2008-11-04 | — | — | US | disclosed |
| US-20080267868-A1 | Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex | NIHON MEDI-PHYSICS, CO., LTD. (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1307239-B1 | RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX | NIHON MEDIPHYSICS CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| EP-1973923-A1 | INTERMEDIATE COMPOUND OF TECHNETIUM NITRIDE COMPLEX FOR RADIODIAGNOSTIC IMAGING | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007083395-A1 | INTERMEDIATE COMPOUND OF TECHNETIUM NITRIDE COMPLEX FOR RADIODIAGNOSTIC IMAGING | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2007-07-26 | — | — | WO | disclosed |
| EP-1307239-A4 | RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX | NIHON MEDIPHYSICS CO LTD (JP) | 2005-01-26 | — | — | EP | disclosed |
| US-20040018147-A1 | Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2004-01-29 | — | — | US | disclosed |
| EP-1307239-A1 | RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX | Nihon Medi-Physics Co., Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002009771-A1 | RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160615-A1 | INTERMEDIATE COMPOUND OF TECHNETIUM NITRIDE COMPLEX FOR RADIODIAGNOSTIC IMAGING | MEN1, NCDN, C1R | ALDH1A1 4466/4885LMNA 2957/4885SMN1; SMN2 2133/4885 |
| US-20080267868-A1 | Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex | PNP, SHBG, NPPA | ALDH1A1 4439/4885LMNA 3366/4885SMN1; SMN2 4368/4885 |
| US-20040018147-A1 | Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex | SHBG, TNNT2, TNNI3 | ALDH1A1 4698/4885LMNA 3596/4885SMN1; SMN2 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.